| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The primary mechanism of (1R,3R)-Ferroptosis inducer-1 is to induce ferroptosis, a cell death pathway characterized by the iron-dependent accumulation of lethal lipid reactive oxygen species (ROS). While the precise direct molecular target of this inducer is not fully specified in the provided summaries, inducers of ferroptosis generally act by either inhibiting system Xc- (cystine/glutamate antiporter) or by directly inhibiting GPX4 (glutathione peroxidase 4), leading to lipid peroxidation.
|
|---|---|
| ln Vitro |
The specific in vitro activity is the induction of ferroptotic cell death in cancer cell lines. This process can be measured by the loss of cell viability, which is distinct from apoptosis. It is typically accompanied by morphological changes such as mitochondrial shrinkage and increased membrane density. The activity can be blocked by specific ferroptosis inhibitors, such as ferrostatin-1 and liproxstatin-1, which are used as controls to confirm the mechanism of cell death.
|
| ln Vivo |
No specific in vivo data was found for (1R,3R)-Ferroptosis inducer-1 in the provided literature. As an inducer of ferroptosis with antitumor potential, it would be evaluated in mouse xenograft models. In such studies, the compound would be administered (e.g., intraperitoneally) to mice bearing tumors, and the reduction in tumor growth would be measured. Its efficacy would be compared to known chemotherapeutic agents.
|
| Enzyme Assay |
A standard cell-free assay for assessing lipid peroxidation is the TBARS (Thiobarbituric Acid Reactive Substances) assay. In this assay, cell lysates or tissue homogenates are incubated with 0.1 M HCl and 0.2% TBA (thiobarbituric acid) in a boiling water bath for 15 minutes. After cooling, the pink chromogen (a malondialdehyde-TBA adduct) is extracted with n-butanol, and the absorbance is measured at 532 nm. This is a general measure of lipid peroxidation, not specific to ferroptosis.
|
| Cell Assay |
A standard cell viability protocol for studying ferroptosis: HT-1080 human fibrosarcoma cells (which are sensitive to ferroptosis) are seeded in DMEM + 10% FBS in 96-well plates. The next day, cells are treated with (1R,3R)-Ferroptosis inducer-1 at concentrations ranging from 0.001 to 100 uM for 24-72 hours. To confirm that cell death is specifically due to ferroptosis, parallel sets of wells are also treated with the inducer in combination with 1 uM ferrostatin-1 or 100 nM liproxstatin-1. Cell viability is measured by the CellTiter-Glo luminescent assay.
|
| Animal Protocol |
No specific in vivo protocol was found for this compound. A general protocol for testing a ferroptosis inducer in a mouse model: 6-8 week old female nude mice are implanted subcutaneously with 5×10⁶ cancer cells (e.g., HT-1080 cells). When tumors reach approximately 150 mm3, mice are randomized into groups (n=8-10 per group): (1) vehicle control; (2) (1R,3R)-Ferroptosis inducer-1 at low dose (e.g., 10 mg/kg); (3) inducer at high dose (e.g., 30 mg/kg); (4) positive control chemotherapeutic. The inducer is administered intraperitoneally daily for 14 days. Tumor volume is measured twice weekly.
|
| ADME/Pharmacokinetics |
No PK data was found for (1R,3R)-Ferroptosis inducer-1. As a small-molecule inducer of ferroptosis, its PK properties (absorption, half-life, clearance) are not described. If it shares properties with other known inducers like erastin or RSL3, it may have low oral bioavailability and require intraperitoneal administration for in vivo work.
|
| Toxicity/Toxicokinetics |
No toxicity data was found for (1R,3R)-Ferroptosis inducer-1. As an inducer of ferroptosis, its off-target toxicity could be significant, as it would induce ferroptosis in normal tissues, particularly in the kidneys and the nervous system, which are known to be susceptible to this form of cell death. It is a research chemical and is not intended for therapeutic use.
|
| References | |
| Additional Infomation |
(1R,3R)-Ferroptosis inducer-1 is a research-grade compound for laboratory use only. Its CAS number is 2375357-97-2, molecular formula is C25H21ClN2O5, and molecular weight is 464.90. It is an isomer of Ferroptosis inducer-1 and is supplied with a purity of ≥98%. This product is used for non-clinical research in cancer biology and the study of regulated cell death pathways. It is not for human therapeutic use. Each product in one row, fields tab-separated.
|
| Molecular Formula |
C25H21CLN2O5
|
|---|---|
| Molecular Weight |
464.90
|
| Exact Mass |
464.114
|
| CAS # |
2375357-97-2
|
| Related CAS # |
Ferroptosis inducer-1;2375357-96-1
|
| PubChem CID |
139446890
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
33
|
| Complexity |
802
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
COC(=O)[C@H]1CC2=C([C@H](N1C(=O)CCl)C3=CC=C(C=C3)C(=O)OCC#C)NC4=CC=CC=C24
|
| InChi Key |
AEFRDVDAQLIGSO-NFBKMPQASA-N
|
| InChi Code |
InChI=1S/C25H21ClN2O5/c1-3-12-33-24(30)16-10-8-15(9-11-16)23-22-18(17-6-4-5-7-19(17)27-22)13-20(25(31)32-2)28(23)21(29)14-26/h1,4-11,20,23,27H,12-14H2,2H3/t20-,23-/m1/s1
|
| Chemical Name |
methyl (1R,3R)-2-(2-chloroacetyl)-1-(4-prop-2-ynoxycarbonylphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-3-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~215.10 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1510 mL | 10.7550 mL | 21.5100 mL | |
| 5 mM | 0.4302 mL | 2.1510 mL | 4.3020 mL | |
| 10 mM | 0.2151 mL | 1.0755 mL | 2.1510 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
